Primary hyperaldosteronism and endothelial ischemia-reperfusion injury

Primary hyperaldosteronism and endothelial ischemia-reperfusion injury - Primary hyperaldosteronism and ischemia-reperfusion injury

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38730

Enrollment

Registered

2013-10-17

Start date

2013-11-06

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism primary hyperaldosteronism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: For patients with primary hyperaldosteronism: -Age 18-75 years -Confirmed primary hyperaldosteronism (aldosterone >0.28 nmol/L after salt loading) -Serum potassium >= 3.5 mmol/L (with or without potassium supplementation) -Written informed consent;For control patients with primary (essential) hypertension: - Age 18-75 years - Primary hypertension - Baseline aldosterone = 3.5 mmol/L - Written informed consent

Exclusion criteria

Exclusion criteria: -Smoking -History of atherosclerotic disease (myocardial infarction (MI), stroke, or peripheral vascular disease) -Not possible to change the antihypertensive medication into only diltiazem with or without hydralazine, or to temporarily stop statins according to the treating physician -Severe renal dysfunction (MDRD

Design outcomes

Primary

Measure	Time frame
To study whether forearm IR impairs brachial artery FMD to a greater extent in patients with hypertension due to PHA than in patients with primary hypertension.	—

Secondary

Measure	Time frame
To study whether CD73 activity on mononuclear cells is lower in patients with PHA, compared to patients with primary hypertension To study whether the circulating adenosine concentration in lower in patients with PHA	—

Countries

Netherlands

Outcome results